Literature DB >> 18519902

Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.

Elham Rahme1, Kaberi Dasgupta, Mark Burman, Hongjun Yin, Sasha Bernatsky, Greg Berry, Hacene Nedjar, Susan R Kahn.   

Abstract

BACKGROUND: Patients undergoing hip or knee replacement are at high risk of developing a postoperative venous thromboembolism even after discharge from hospital. We sought to identify hospital and patient characteristics associated with receiving thromboprophylaxis after discharge and to compare the risk of short-term mortality among those who did or did not receive thromboprophylaxis.
METHODS: We conducted a retrospective cohort study using system-wide hospital discharge summary records, physician billing information, medication reimbursement claims and demographic records. We included patients aged 65 years and older who received a hip or knee replacement and who were discharged home after surgery.
RESULTS: In total we included 10 744 patients. Of these, 7058 patients who received a hip replacement and 3686 who received a knee replacement. The mean age was 75.4 (standard deviation [SD] 6.8) years and 38% of patients were men. In total, 2059 (19%) patients received thomboprophylaxis at discharge. Patients discharged from university teaching hospitals were less likely than those discharged from community hospitals to received thromboprophylaxis after discharge (odds ratio [OR] 0.89, 95% confidence interval [CI] 0.80-1.00). Patients were less likely to receive thromboprophylaxis after discharge if they had a longer hospital stay (15-30 days v. 1-7 days, OR 0.69, 95% CI 0.59-0.81). Patients were more likely to receive thromboprophylaxis if they had hip (v. knee) replacement, osteoarthritis, heart failure, atrial fibrillation or hypertension, higher (v. lower) income or if they were treated at medium-volume hospitals (69-116 hip and knee replacements per year). In total, 223 patients (2%) died in the 3-month period after discharge. The risk of short-term mortality was lower among those who received thromboprophylaxis after discharge (hazard ratio [HR] 0.34, 95% CI 0.20-0.57).
INTERPRETATION: Fewer than 1 in 5 elderly patients discharged home after a hip-or knee-replacement surgery received postdischarge thromboprophylaxis. Those prescribed these medications had a lower risk of short-term mortality. The benefits of and barriers to thromboprophylaxis therapy after discharge in this population requires further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519902      PMCID: PMC2396368          DOI: 10.1503/cmaj.071388

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  29 in total

Review 1.  Prevention of venous thromboembolism.

Authors:  W H Geerts; J A Heit; G P Clagett; G F Pineo; C W Colwell; F A Anderson; H B Wheeler
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment.

Authors:  R Tamblyn; T Reid; N Mayo; P McLeod; M Churchill-Smith
Journal:  J Clin Epidemiol       Date:  2000-02       Impact factor: 6.437

3.  Mortality after total hip and knee arthroplasty in a medium-volume university practice.

Authors:  Ryan M Nunley; Paul F Lachiewicz
Journal:  J Arthroplasty       Date:  2003-04       Impact factor: 4.757

Review 4.  Prevention of venous thromboembolism.

Authors:  Mario Pini; Alex C Spyropoulos
Journal:  Semin Thromb Hemost       Date:  2006-11       Impact factor: 4.180

Review 5.  Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.

Authors:  R D Hull; G F Pineo; P D Stein; A F Mah; S M MacIsaac; O E Dahl; M Butcher; R F Brant; W A Ghali; D Bergqvist; G E Raskob
Journal:  Ann Intern Med       Date:  2001-11-20       Impact factor: 25.391

6.  Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.

Authors:  J W Eikelboom; D J Quinlan; J D Douketis
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

7.  Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership.

Authors:  J W Mesko; R A Brand; R Iorio; I Gradisar; R Heekin; R Leighton; R Thornberry
Journal:  J Arthroplasty       Date:  2001-09       Impact factor: 4.757

8.  Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study.

Authors:  Paolo Prandoni; Olinto Bruchi; Paola Sabbion; Cinzia Tanduo; Alberta Scudeller; Corrado Sardella; Gabriella Errigo; Francesco Pietrobelli; Gianni Maso; Antonio Girolami
Journal:  Arch Intern Med       Date:  2002-09-23

Review 9.  Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Mark N Levine; Gary Raskob; Rebecca J Beyth; Clive Kearon; Sam Schulman
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

10.  Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999.

Authors:  Stein Atle Lie; Lars Birger Engesaeter; Leif Ivar Havelin; Ove Furnes; Stein Emil Vollset
Journal:  Acta Orthop Scand       Date:  2002-08
View more
  11 in total

1.  Retrospective analysis of adherence to thromboprophylaxis after orthopedic surgery in a community hospital.

Authors:  Megan A McElwee; Aaron Tejani; Lily Cheng
Journal:  Can J Hosp Pharm       Date:  2010-03

Review 2.  Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns.

Authors:  William D Fisher; Alexander G G Turpie
Journal:  CMAJ       Date:  2008-06-03       Impact factor: 8.262

Review 3.  Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.

Authors:  Vladimir Trkulja; Robert Kolundzic
Journal:  Croat Med J       Date:  2010-04       Impact factor: 1.351

4.  Short-term mortality associated with failure to receive home care after hemiarthroplasty.

Authors:  Elham Rahme; Susan R Kahn; Kaberi Dasgupta; Mark Burman; Sasha Bernatsky; Youssef Habel; Greg Berry
Journal:  CMAJ       Date:  2010-08-16       Impact factor: 8.262

5.  Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.

Authors:  Richard J Friedman
Journal:  Thrombosis       Date:  2010-09-13

6.  The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery.

Authors:  Yuan Gao; Anhua Long; Zongyan Xie; Yutong Meng; Jing Tan; Houchen Lv; Licheng Zhang; Lihai Zhang; Peifu Tang
Journal:  Springerplus       Date:  2016-08-18

7.  Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.

Authors:  Ho-Young Yhim; Juhyun Lee; Ji Yun Lee; Jeong-Ok Lee; Soo-Mee Bang
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

8.  Geriatric Patient Safety Indicators Based on Linked Administrative Health Data to Assess Anticoagulant-Related Thromboembolic and Hemorrhagic Adverse Events in Older Inpatients: A Study Proposal.

Authors:  Marie-Annick Le Pogam; Catherine Quantin; Oliver Reich; Philippe Tuppin; Anne Fagot-Campagna; Fred Paccaud; Isabelle Peytremann-Bridevaux; Bernard Burnand
Journal:  JMIR Res Protoc       Date:  2017-05-11

9.  Ten-Year Trends in Medical Complications Following 540,623 Primary Total Hip Replacements from a National Database.

Authors:  Thomas Partridge; Simon Jameson; Paul Baker; David Deehan; James Mason; Mike R Reed
Journal:  J Bone Joint Surg Am       Date:  2018-03-07       Impact factor: 5.284

Review 10.  What has changed in venous thromboembolism prophylaxis for hospitalized patients over recent decades: review article.

Authors:  Selma Regina de Oliveira Raymundo; Suzana Margareth Ajeje Lobo; Kassim Mohamede Kassim Hussain; Kassim Guzzon Hussein; Isabela Tobal Secches
Journal:  J Vasc Bras       Date:  2019-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.